Table 4.
Therapeutic proposal.
| NGS-based proposals | ||
|---|---|---|
| Patients with therapeutic proposal after NGS analysis. n (%) | N = =456 | |
| Yes | 342 (75) | |
| No | 114 (25) | |
| Treatment based on NGS analysis at disease progression. n (%) | N = =342 | |
| Yes | 79 (23.1) | |
| No | 263 (76.9) | |
| Type of treatment delivered according to NGS analysis | N = =79 | |
| PIK3/AKT/mTOR inhibitors | 22 (27.8) | |
| PARP inhibitors | 19 (24.1) | |
| Antiangiogenics | 17 (21.5) | |
| MEK inhibitors | 7 (8.9) | |
| Immunotherapy | 5 (6.3) | |
| Other | 9 (11.4) | |
| End of treatment according to NGS analysis | ||
| Progression disease | 34 (43) | |
| Toxicity | 5 (6.3) | |
| Death | 4 (5.1) | |
| Other | 9 (11.4) | |
| Unknown | 27 (34.2) | |
| Reason for no treatment delivery | N = =263 | |
| Other therapy | 149 (56.7) | |
| No further therapy | 114 (43.3) | |
| Palliative care | 66 (57.9) | |
| Death | 40 (35.1) | |
| Other | 8 (7) | |